📊 CGON Key Takeaways
Investment Thesis
CG Oncology is a pre-revenue biotech company with severe cash burn (-$132.3M operating cash flow) against minimal revenue ($4.0M), indicating extended path to profitability. Critically low liquidity relative to burn rate (32.5M cash against -$132.5M free cash flow) suggests potential funding challenges within 3-4 quarters without capital raises.
CGON Strengths
- Strong balance sheet with $752.6M stockholders' equity and zero net debt
- Exceptional liquidity ratios (24.63x current ratio) providing short-term solvency
- Rapid revenue growth (+254.7% YoY) indicating commercial traction in early stage
- Substantial asset base ($791.6M) providing resources for development
CGON Risks
- Unsustainable cash burn rate of -$132.3M annually against only $32.5M cash on hand
- Extreme negative profitability metrics (-4722% operating margin, -3985% net margin) with no path to breakeven visible
- Net income loss of -$161.0M in latest period indicates massive R&D and operational expenses
- Minimal revenue base ($4.0M) insufficient to offset operating expenses, requiring continued dilutive financing
Key Metrics to Watch
- Quarterly cash burn rate and runway to profitability
- Revenue growth trajectory and pipeline advancement milestones
- Capital raised and dilution impact on shareholder equity
- Operating expense reduction and path toward operating cash flow breakeven
CGON Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 24.63x current ratio provides a solid financial cushion.
CGON Profitability Ratios
CGON vs Healthcare Sector
How CG Oncology, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
CGON Balance Sheet & Liquidity
CGON 5-Year Financial Trend
5-Year Trend Summary: CG Oncology, Inc.'s revenue has grown significantly by 255% over the 5-year period, indicating strong business expansion. The most recent EPS of $-15.65 indicates the company is currently unprofitable.
CGON Growth Metrics (YoY)
CGON Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $43.0K | -$16.9M | $-0.30 |
| Q2 2025 | N/A | -$16.9M | $-0.28 |
| Q1 2025 | $52.0K | -$16.9M | $-0.36 |
| Q3 2024 | $9.0K | -$8.7M | $-0.30 |
| Q2 2024 | N/A | -$8.7M | $-0.28 |
| Q1 2024 | $194.0K | -$8.7M | $-0.36 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
CGON Capital Allocation
CGON SEC Filings
Access official SEC EDGAR filings for CG Oncology, Inc. (CIK: 0001991792)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CGON
What is the AI rating for CGON?
CG Oncology, Inc. (CGON) has an AI rating of SELL with 92% confidence, based on fundamental analysis of SEC EDGAR filings.
What are CGON's key strengths?
Strong balance sheet with $752.6M stockholders' equity and zero net debt. Exceptional liquidity ratios (24.63x current ratio) providing short-term solvency.
What are the risks of investing in CGON?
Unsustainable cash burn rate of -$132.3M annually against only $32.5M cash on hand. Extreme negative profitability metrics (-4722% operating margin, -3985% net margin) with no path to breakeven visible.
What is CGON's revenue and growth?
CG Oncology, Inc. reported revenue of $4.0M.
Does CGON pay dividends?
CG Oncology, Inc. does not currently pay dividends.
Where can I find CGON SEC filings?
Official SEC filings for CG Oncology, Inc. (CIK: 0001991792) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CGON's EPS?
CG Oncology, Inc. has a diluted EPS of $-2.08.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.